N4 Pharma PLC (N4P) Earns Speculative Buy Rating from Beaufort Securities
N4 Pharma PLC (LON:N4P)‘s stock had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities in a note issued to investors on Tuesday. They presently have a GBX 12 ($0.16) target price on the stock. Beaufort Securities’ target price suggests a potential upside of 113.52% from the company’s previous close.
N4 Pharma PLC (N4P) opened at 5.375 on Tuesday. N4 Pharma PLC has a 52 week low of GBX 1.20 and a 52 week high of GBX 12.50. The company has a 50-day moving average of GBX 5.87 and a 200-day moving average of GBX 6.78. The firm’s market cap is GBX 4.02 million.
TRADEMARK VIOLATION NOTICE: “N4 Pharma PLC (N4P) Earns Speculative Buy Rating from Beaufort Securities” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/26/n4-pharma-plc-n4p-earns-speculative-buy-rating-from-beaufort-securities.html.
About N4 Pharma PLC
N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.
Receive News & Ratings for N4 Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.